Metraipolis › archive › dc_526053eafbc4

Real-World Outcomes of Combined Carbon-Ion Radiotherapy and Systemic Immunotherapy for Hepatocellular Carcinoma (Atezolizumab Plus Bevacizumab or Durvalumab… — Europe PMC PMID:42513363

Source
Europe PMC (en)
Original
https://europepmc.org/article/MED/42513363
DOI
10.3390/jcm15145449
License (as archived)
solo-consultazione
Archived
2026-10-18T07:57:42.377Z
SHA-256 of the archived text
14cca96d330e2bcae2bb01be24444e56c9ae6c121b92091ad832bc3db45cf2d5
Stable URL of this page
https://metraipolis.com/documento/dc_526053eafbc4

How to cite

Real-World Outcomes of Combined Carbon-Ion Radiotherapy and Systemic Immunotherapy for Hepatocellular Carcinoma (Atezolizumab Plus Bevacizumab or Durvalumab… — Europe PMC PMID:42513363 — Europe PMC (en), https://europepmc.org/article/MED/42513363 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_526053eafbc4 (Metraipolis archive dc_526053eafbc4, sha256 14cca96d330e2bcae2bb01be24444e56c9ae6c121b92091ad832bc3db45cf2d5)
BibTeX
@misc{dc526053eafbc4,
  title = {Real-World Outcomes of Combined Carbon-Ion Radiotherapy and Systemic Immunotherapy for Hepatocellular Carcinoma (Atezolizumab Plus Bevacizumab or Durvalumab… — Europe PMC PMID:42513363},
  howpublished = {Europe PMC (en)},
  url = {https://europepmc.org/article/MED/42513363},
  note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_526053eafbc4; sha256 14cca96d330e2bcae2bb01be24444e56c9ae6c121b92091ad832bc3db45cf2d5},
  year = {2026}
}

Archived text

The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/42513363. Agents can read the archived copy with the MCP tool read_document.